Global Intravenous Immune Globulin Therapies Market Growth (Status and Outlook) 2025-2031

According to this study, the global Intravenous Immune Globulin Therapies market size will reach US$ million by 2031.

Immune globulin derived from the plasma of paid and volunteer donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders.

United States market for Intravenous Immune Globulin Therapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Intravenous Immune Globulin Therapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Intravenous Immune Globulin Therapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Intravenous Immune Globulin Therapies players cover Baxter, Grifols, CSL Plasma, Octapharma, Biotest, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Intravenous Immune Globulin Therapies Industry Forecast” looks at past sales and reviews total world Intravenous Immune Globulin Therapies sales in 2024, providing a comprehensive analysis by region and market sector of projected Intravenous Immune Globulin Therapies sales for 2025 through 2031. With Intravenous Immune Globulin Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravenous Immune Globulin Therapies industry.

This Insight Report provides a comprehensive analysis of the global Intravenous Immune Globulin Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Intravenous Immune Globulin Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravenous Immune Globulin Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravenous Immune Globulin Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravenous Immune Globulin Therapies.

This report presents a comprehensive overview, market shares, and growth opportunities of Intravenous Immune Globulin Therapies market by product type, application, key players and key regions and countries.

Segmentation by Type:
Liquid Form
Lyophilized Powder Form

Segmentation by Application:
Immunodeficiency
Autoimmune Disease
Acute Infection

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxter
Grifols
CSL Plasma
Octapharma
Biotest
Kedrion
Kamada
China Biologic Products Holdings
Hualan Biological Engineering
Sichuan Yuanda Shuyang Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver. Show more